Sign In
Buy OYST
$11.17
+0 (+0%)
At Close: Mar 29, 2023
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q1 2020 Results - Earnings Call Transcript
07:46pm, Monday, 11'th May 2020
Oyster Point Pharma Inc (NASDAQ:OYST) Q1 2020 Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Daniel Lochner – Chief Financial Officer Jef
Oyster Point Pharma, Inc. (OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surf
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights
10:00am, Monday, 11'th May 2020
Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Oyster Point Pharma to Report First Quarter 2020 Financial Results on May 11, 2020
08:05pm, Monday, 04'th May 2020
Oyster Point Pharma, Inc. (OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surf
Bank of New York Mellon Corp Makes New Investment in Oyster Point Pharma (NASDAQ:OYST)
09:18am, Friday, 01'st May 2020
Bank of New York Mellon Corp bought a new position in shares of Oyster Point Pharma (NASDAQ:OYST) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and
Zacks: Analysts Set $50.00 Target Price for Oyster Point Pharma (NASDAQ:OYST)
10:08am, Saturday, 11'th Apr 2020
Oyster Point Pharma (NASDAQ:OYST) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. T
Coronavirus renders sport fishing season 'dead in the water'
11:05pm, Monday, 30'th Mar 2020
Amid fears over the spread of COVID-19, party boats and coastal launch ramps have been shut down for Wednesday’s scheduled opening of the Bay Area coast deep-sea fishing season — and also for Satu
PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of firs
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
09:01pm, Thursday, 27'th Feb 2020
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139.1 million as of December 31, 2019 Conference Call and Webcast Scheduled for 4:30 pm.
Oyster Point Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
01:00pm, Monday, 24'th Feb 2020
PRINCETON, N.J., Feb. 24, 2020 -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and.
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
12:12pm, Tuesday, 28'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmace
The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study
12:43pm, Friday, 24'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter Int
Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease
01:00am, Monday, 13'th Jan 2020
Oyster Point Pharma, Inc. (OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surf
